Memorial Sloan Kettering Cancer Center

The combination of KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) demonstrated a 16.7% five-year overall survival rate in patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the Phase 3 KEYNOTE-775/Study 309 trial.

General Oncology will present preliminary Phase 1 results from the SHARON trial evaluating GO-4 therapy in patients with BRCA/PALB2-mutated pancreatic and breast cancers at ESMO 2025.

SELLAS Life Sciences will host a virtual R&D Day on October 29, 2025, featuring key opinion leaders discussing acute myeloid leukemia treatment advances and unmet medical needs.

Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment.

Myriad Genetics and SOPHiA GENETICS announced a strategic collaboration to develop an innovative global liquid biopsy companion diagnostic test for pharmaceutical companies.

GeneDx appointed Lisa Gurry as Chief Business Officer to lead strategic partnerships and unlock the potential of GeneDx Infinity, the world's largest rare disease dataset with nearly one million exomes and genomes.

FORE Biotherapeutics presented Phase 1/2a data showing plixorafenib achieved a median progression-free survival of 64 months and 85.7% clinical benefit rate in MAPK inhibitor-naïve BRAF V600-mutated papillary thyroid cancer patients.

Perioperative nivolumab demonstrated no negative impact on health-related quality of life while reducing the risk of deterioration compared to placebo in patients with stage III N2 or non-N2 non-small cell lung cancer.

BostonGene published a study in Cell Reports Medicine introducing the largest harmonized transcriptomic and clinical dataset in kidney cancer, analyzing over 3,600 patient samples.

Abdera Therapeutics presented initial Phase 1 clinical data for ABD-147, a novel DLL3-targeting radiopharmaceutical delivering Actinium-225 to small cell lung cancer tumors.